Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201

NCT01540409 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT01540409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01540409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2012
Completion date
August 16, 2017
Enrollment
12 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)